Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
In this post hoc analysis of the CLEAR Outcomes randomized clinical trial, investigators evaluated whether bempedoic acid reduces the risk of venous thromboembolism (VTE) in statin-intolerant patients at high cardiovascular risk.
A total of 13,970 participants (mean age 65.5 years; 48.2% women) were randomized to bempedoic acid 180 mg daily or placebo and followed for a median of 40.6 months.
During follow-up, 106 VTE events occurred.
Bempedoic acid was associated with a significant 42% relative reduction in VTE compared with placebo (39 vs 67 events; HR 0.58, 95% CI 0.39–0.86; P=0.006).
Consistent benefits were observed for both major components of VTE: deep vein thrombosis (HR 0.56, 95% CI 0.31–0.996; P=0.045) and pulmonary embolism (HR 0.61, 95% CI 0.37–0.996; P=0.046).
These findings extend previous evidence suggesting that lipid-lowering therapies may provide protection beyond atherosclerotic cardiovascular disease, potentially reducing thrombotic events through anti-inflammatory effects, lipoprotein(a) reduction, and enhanced clearance of coagulation factors.
Importantly, the observed reduction in VTE persisted even after accounting for major cardiovascular events.
Although limited by its post hoc design and the relatively small number of VTE events, this analysis suggests that bempedoic acid may offer an additional clinical benefit in statin-intolerant patients by lowering both cardiovascular and venous thromboembolic risk.
These results should be considered hypothesis-generating and warrant prospective confirmation.”
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 07:55A New Era of Precision Imaging for Venous Thromboembolism – JTH
-
Jul 21, 2026, 07:43How to Monitor and Manage Unfractionated Heparin in Practice – JTH
-
Jul 21, 2026, 07:23Arthur Allen: Advancing Outpatient Antithrombotic Stewardship Through ADAPT
-
Jul 21, 2026, 03:19Where Does Stroke Treatment Go Next on The Latest ESOC 2026 TV Studio Session – ESO
-
Jul 21, 2026, 03:09Francesca Palandri: New Insights Into Anemia Management in Myelofibrosis
-
Jul 21, 2026, 01:57A New Approach to Understanding Plasmin Generation and Fibrinolysis – RPTH Journal
-
Jul 21, 2026, 01:52Maria Diaz Alonso: Delivering My First International Oral Presentation at ISTH 2026
-
Jul 21, 2026, 01:44Megan Preece: Presenting New Research on Antiphospholipid Syndrome at ISTH 2026
-
Jul 21, 2026, 01:28Dhamirah Nazihah Mohd Nasiruddin: A Milestone in My Haemostasis and Thrombosis Journey at ISTH 2026